Article Text

PDF
Potassium para-aminobenzoate (potaba) in scleroderma

Abstract

In the past fifteen years there have been numerous reports on the treatment of scleroderma and related conditions with potassium para-aminobenzoate (Potaba - Glenwood Laboratories). The use of this ‘antifibrotic’ treatment is empirical. p-Aminobenzoic acid (PABA) is not known to affect fibrosis or fibrous tissue experimentally. Many bacteria require it for the synthesis of folic acid, and sulphonamides antagonise their utilisation of it.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.